Clinical trial · Interventional
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was terminated per PI decision.
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cryoablation kills cancer cells by freezing them. Giving chemotherapy together with cryoablation may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving cyclophosphamide together with cryoablation works in treating patients with advanced or metastatic epithelial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cryoablation | Device | — | UNRESOLVED |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
- interventionNames
- Drug: cyclophosphamide
- Device: Cryoablation
Primary outcomes (1)
- measure
- Safety, in terms of absences of severe adverse events (SAE) and unacceptable toxicity
- timeFrame
- Two years
Secondary outcomes (1)
- measure
- Tumor response, according to RECIST criteria
- timeFrame
- Two years
- description
- tumor response will be measured according to RECIST (Response Evaluation Criteria In Solid Tumors) criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of epithelial solid tumors of any of the following sites or types: * Lung (closed to accrual as of 4/2/2009) * Renal * Prostate * Breast (closed to accrual as of 4/2/2009) * Sarcoma (closed to accrual as of 4/2/2009) * Colon (closed to accrual as of 4/2/2009) * Liver(closed to accrual as of 4/2/2009) * Pancreatic (closed to accrual as of 4/2/2009) * Bone (closed to accrual as of 4/2/2009) * Head and neck (closed to accrual as of 4/2/2009) * Melanoma (closed to accrual as of 4/2/2009) * Carcinoma of unknown primary (closed to accrual as of 4/2/2009) * Advanced or metastatic disease * Ineligible for or unwilling to undergo surgical resection * Eligible for cryotherapy but not expected to be cured by cryotherapy alone PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy \> 3 months * Creatinine \< 2.5 mg/dL * Platelet count \>75,000/mm³ * INR\< 1.5 * No known HIV positivity * No active, uncontrolled infection * Not pregnant * Negative pregnancy test * Women of childbearing potential must practice adequate contraception * No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available